Understanding how certain proteins are targeted for degradation in cells
Substrate targeting mechanism of a DesCEND pathway
['FUNDING_R01'] · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · NIH-10624332
This study is looking at how a protein called FBXO31 helps decide which other proteins in our cells should be broken down, which could help us understand diseases like cancer that happen when proteins aren't managed properly.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CONNECTICUT SCH OF MED/DNT (nih funded) |
| Locations | 1 site (FARMINGTON, UNITED STATES) |
| Trial ID | NIH-10624332 on ClinicalTrials.gov |
What this research studies
This research investigates the mechanisms by which specific proteins are marked for degradation within cells, focusing on a protein called FBXO31 that plays a crucial role in this process. By studying the interactions between FBXO31 and its protein substrates, particularly those containing a specific degradation signal known as a PEST motif, the research aims to uncover how these proteins are recognized and processed. The approach involves advanced techniques such as X-ray crystallography to visualize these interactions at a molecular level, which could lead to insights into cellular regulation and stability. Patients may benefit from this research as it could enhance our understanding of diseases related to protein mismanagement, such as cancer.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research would include individuals with conditions related to protein mismanagement, such as certain cancers.
Not a fit: Patients with stable conditions unrelated to protein degradation processes may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for diseases caused by protein degradation dysfunction.
How similar studies have performed: Other research has shown success in understanding protein degradation pathways, making this approach promising and relevant.
Where this research is happening
FARMINGTON, UNITED STATES
- UNIVERSITY OF CONNECTICUT SCH OF MED/DNT — FARMINGTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HAO, BING — UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
- Study coordinator: HAO, BING
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.